Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
VivaMab and ADC Therapeutics Sarl announced a licensing deal for a novel antibody against an undisclosed hematological cancer target.

VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), today announced a licensing deal for a novel antibody against an undisclosed hematological cancer target.

Under the terms of the deal, ADC Therapeutics has licensed a VivaMab antibody (VM101) produced using BioAtla’s Express Humanization™, Comprehensive Positional Evolution™, Combinatorial Protein Synthesis™ affinity and functional maturation technology platforms. VM101 has been combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a novel ADC, which has already been shown to have powerful in vivo efficacy in established models for normally intractable hematological cancer indications.

ADC Therapeutics plans to initiate pre-IND development of this proprietary ADC immediately, in parallel with its other advanced ADC programs. VivaMab will provide development support and will receive a share of potential milestones and royalties on the drug. Financial terms were not disclosed and remain confidential.

Dr. William Boyle, President of VivaMab said: “The BioAtla platform has generated a superior internalizing antibody to the target of interest, allowing us to generate and develop an ADC drug candidate for hematologic cancers. The combination of a uniquely potent BioAtla antibody with a potent drug conjugate, or warhead, is likely to enhance therapeutic outcomes in its target indication.”

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics said: “PBD-antibody conjugates are the most promising next-generation ADCs. The target disease for this ADC is particularly sensitive to our PBD technology, with its functionally optimized conjugation and pharmaceutical properties that maintain activity in cancers resistant to other therapies including earlier generations of ADCs. We are very pleased to be working with VivaMab to bring this potentially exciting cancer therapeutic into clinical development.”

Results presented at the 2013 American Association for Cancer Research by BioAtla and Spirogen showed positive data describing the potent ADC activity which resulted from the combination of BioAtla’s functionally and CIAO!™ evolved antibody with Spirogen’s PBD-derived conjugate. The pre-clinical studies, that evaluated in vivo performance against a hematologic cancer target, showed complete responses at low doses, and at low drug-antibody ratios, in each of the tumor types studied. The PBD dimers were not found to be cross-resistant with widely used chemotherapeutic agents.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ADC Therapeutics Expands Team
Company’s lead program, ADCT-301, to enter clinical development in early 2015.
Wednesday, October 08, 2014
Prostrate Cancer Drug Moves into Human Clinical Trials
ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune.
Monday, May 19, 2014
ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics
Adds an additional proprietary ADC development program in oncology.
Thursday, November 07, 2013
ADC Therapeutics and BZL Biologics Announces Licensing and Collaboration Agreement
Company licenses proprietary antibody from BZL Biologics for prostate cancer.
Tuesday, July 16, 2013
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!